Results 71 to 80 of about 205,670 (312)

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Ki-67 protein expression and tumor associated inflammatory cells (macrophages and mast cells) in canine colorectal carcinoma

BMC Veterinary Research, 2017
Background Ki67 index, tumor associated macrophages (TAMs) and mast cells (MCs) are associated with malignancies in animal and human neoplasms including colorectal carcinomas (CRC). This has not been assessed in canine CRC.
M. Woldemeskel, I. Hawkins, L. Whittington   +2 more
doaj   +1 more source

An ex vivo study of the effects of co-surfactants and conditioning additives on hair colour protection [PDF]

, 2014
This poster was exhibited as part of the Beauty and Life Science section of the Scientific ...
Daniels, Gabriela, Grant-Ross, Peter, Katakami, Kristin, Tamburic, Slobodanka   +3 more
core  

Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial [PDF]

, 2014
David R Coghill,1 Tobias Banaschewski,2 Michel Lecendreux,3 César Soutullo,4 Alessandro Zuddas,5 Ben Adeyi,6 Shaw Sorooshian7 1Division of Neuroscience, University of Dundee, Dundee, UK; 2Child and Adolescent Psychiatry and Psychotherapy, Central
Alessandro Alessandro Zuddas, Ben Adeyi, Cesar Soutullo, David Coghill, Katharine Murkett, Michel Lecendreux, Shaw Sorooshian, Tobias Banaschewski   +7 more
core   +6 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Remarkable response of metaplastic breast cancer to a novel targeted AKT inhibitor TAS-117 in a Cowden syndrome patient: a case report

BJC Reports
PTEN hamartoma tumour syndrome (PHTS) is characterized by a germline PTEN mutation and a substantial increase in lifetime breast cancer risk to 85% with lower age at first diagnosis.
Eva Godina, Marta Fernández Carcaño, Burak Uzunparmak, Thomas Pepper, Pooja Shah, Jordi Rodon   +5 more
doaj   +1 more source

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial [PDF]

Journal of Immunotherapy and Precision Oncology
Introduction Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy with immune checkpoint inhibitors has led to limited improvement in response rates, combination with ...
Mohamed A. Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A. Gurses, Ashabari Sprenger, Yanyan Tian, Mohamed H. Derbala, Isabella Glitza Oliva, Funda Meric-Bernstam, Sapna P. Patel   +10 more
doaj   +1 more source

Characteristics and survival of patients with advanced cancer and p53 mutations. [PDF]

, 2014
P53 mutations are associated with invasive tumors in mouse models. We assessed the p53mutations and survival in patients with advanced cancer treated in the Phase I Program. Of 691 tested patients, 273 (39.5%) had p53 mutations.
Aldape, Kenneth, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Kurzrock, Razelle, Naing, Aung, Palmer, Gary A, Said, Rabih, Thomas, Christoforos, Tsimberidou, Apostolia M, Wheler, Jennifer J, Ye, Yang   +12 more
core   +4 more sources

Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity

Advanced Science, EarlyView.
The inhibitory immune checkpoints HLA‐G and CD47 are expressed on certain tumor types and inhibit immune cells in the tumor microenvironment. DSP216 binds specifically to cancer cells expressing both HLA‐G and CD47, and blocks their inhibitory signaling.
Lisa J. Jacob, Liat Tamir, Mufeed Abdeen, Ami Tamir, Alexandra Aronin, Itai Bloch, Roy Kahn, Iris Pecker, Mark Tykocinski, Gerwin Huls, Yaron Pereg, Ayelet Chajut, Edwin Bremer   +12 more
wiley   +1 more source

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory

Journal for ImmunoTherapy of Cancer, 2020
Introduction Immunotherapies have revolutionized the treatment of various cancers, but little is known about their symptomatic toxicity. Assessing these symptoms is best accomplished by asking the patients themselves. However, such reports are subjective
Vivek Subbiah, Jing Gong, Siqing Fu, Aung Naing, Shubham Pant, Filip Janku, Mehmet Altan, Kenneth Hess, Ajay Sheshadri, Lilibeth Castillo, Bettzy Stephen, David S Hong, Sarina A Piha-Paul, Tito Mendoza, Goldy George, Enedelia Rodriguez, Christine Peterson, Jordi Rodon Ahnert, Ecaterina Dumbrava, Timonthy A Yap, Apostolia M Tsimberidou, Daniel D Karp, Abdulrazzak Zarifa, Lacey M McQuinn, Charles Cleeland   +24 more
doaj   +1 more source